CytoMed Therapeutics (GDTC) Earnings Analysis
CytoMed Therapeutics (GDTC) next reports earnings on 2026-11-13. Trailing P/E -3.06.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does GDTC next report earnings?
| Next earnings date | 2026-11-13 |
|---|---|
| Consensus EPS estimate | n/a |
| Revenue estimate | n/a |
GDTC earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2025-09-30 | -0.07471 USD | n/a | n/a | n/a |
| 2025-03-31 | -0.05251 USD | n/a | n/a | n/a |
| 2024-09-30 | -0.03691 USD | n/a | n/a | n/a |
GDTC valuation and analyst view
| Trailing P/E | -3.06 |
|---|---|
| Trailing EPS | -0.41139 USD |
| Price / book | 2.23 |
| Dividend yield | 0.00% |
| Market cap | 0.01B |
| Analyst consensus | Buy (1 buy / 0 hold / 0 sell) |
Related research pages
Frequently asked questions
When is CytoMed Therapeutics (GDTC)'s next earnings date?
CytoMed Therapeutics is next scheduled to report on 2026-11-13.
Did GDTC beat earnings last quarter?
Consensus estimate data was not available for GDTC's 2025-09-30 report.
What is GDTC's current P/E ratio and EPS?
GDTC trades at a trailing P/E of -3.06 on trailing EPS of -0.4113924963325179 USD.
What do analysts rate GDTC?
Analyst consensus is "Buy" across 1 ratings (0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell).